Talphera (TLPH) Q4 2024 earnings summary

Executive summary

• FDA approved major protocol changes for the NEPHRO CRRT study, reducing size from 166 to 70 patients and broadening inclusion criteria, with completion targeted by end of 2025 and PMA submission in Q1 2025.

• Private placement agreement for up to $14.8 million in gross proceeds, expected to fund operations through study completion, with management and investors, including CEO, participating.

• Niyad, the lead product candidate, continues to receive strong clinical interest and has Breakthrough Device Designation.

Financial highlights

• Cash and investments totaled $8.9 million as of December 31, 2024.

• Q4 2024 R&D and SG&A expenses were $3.0 million, down from $4.6 million in Q4 2023; excluding stock-based compensation, $2.8 million vs. $4.3 million.

• Q4 2024 net loss from continuing operations was $1.9 million, down from $4.5 million in Q4 2023, mainly due to changes in warrant liability value.

• Net loss per share for Q4 2024 was $0.07, compared to $0.25 in Q4 2023.

• Year-end 2024 total assets were $18.2 million, with total liabilities of $10.2 million and stockholders' equity of $8.0 million.

Outlook and guidance

• Cash operating expenses (SG&A and R&D, excluding stock-based compensation) expected to be $18–$19 million in 2025, including NEPHRO CRRT trial costs.

• Anticipated completion of NEPHRO CRRT study by end of 2025, with FDA approval of Niyad targeted for 2026.